The 12th Invest in ME Conference, Part 1
OverTheHills presents the first article in a series of three about the recent 12th Invest In ME international Conference (IIMEC12) in London.
Discuss the article on the Forums.

Aperiomics: pathogen detection via next generation sequencing

Discussion in 'Diagnostic Guidelines and Laboratory Testing' started by Cheesus, Apr 6, 2017.

  1. Cheesus

    Cheesus Senior Member

    I had a highly atypical onset to my ME and continue to have atypical symptoms. Whilst I am confident I share a common endpoint with most of you, I feel that my condition is sufficiently distinct that I might have a unique aetiology.

    The recent paper from Hornig and Lipkin concluded:

    Specifically, my condition deteriorated from chronic ill health to diagnosable ME when I had "die off" from the herbal antimicrobial oil of oregano, which has always made me suspicious that I may have a microbial aetiology. I have always wanted to thoroughly test for possible microbes, but the NHS is useless at investigating atypical chronic conditions. Hornig and Lipkin's new paper has given me fresh motivation to pursue this line of investigation myself, because if I don't then no one will.

    I have recently discovered Aperiomics, which is a company that offers next generation sequencing (NGS) for infectious diseases. The advantage of NGS testing is that it can capture both known and unknown pathogens without needing to form a hypothesis about what those pathogens might be. It is the same technology that uBiome uses to sequence the gut microbiome.

    I'd be interested in hearing other people's opinions about this line of testing (including @alicec). It is going to be very expensive, but to be honest I don't really care. If I were to spend thousands and get no where from it, then so be it.

    What do you guys think?

See more popular forum discussions.

Share This Page